152 related articles for article (PubMed ID: 17204829)
1. Selective serotonin reuptake inhibitors reduce the attack frequency in familial mediterranean Fever.
Onat AM; Oztürk MA; Ozçakar L; Ureten K; Kaymak SU; Kiraz S; Ertenli I; Calgüneri M
Tohoku J Exp Med; 2007 Jan; 211(1):9-14. PubMed ID: 17204829
[TBL] [Abstract][Full Text] [Related]
2. Plasma and platelet serotonin levels in familial Mediterranean fever.
Onat AM; Ozçakar L; Oztürk MA; Uçar G; Ureten K; Dagli N; Kiraz S; Ertenli I; Calgüneri M
Clin Exp Rheumatol; 2007; 25(4 Suppl 45):S16-20. PubMed ID: 17949546
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis.
Varan Ö; Kucuk H; Babaoglu H; Guven SC; Ozturk MA; Haznedaroglu S; Goker B; Tufan A
Mod Rheumatol; 2019 Mar; 29(2):363-366. PubMed ID: 29578360
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of hearing in pediatric familial Mediterranean fever patients during attack period and attack-free period.
Salimov A; Akyol U; Cildir B; Batu ED; Ozen S
Int J Pediatr Otorhinolaryngol; 2019 Apr; 119():185-192. PubMed ID: 30743166
[TBL] [Abstract][Full Text] [Related]
5. Selective serotonin reuptake inhibitors in familial Mediterranean fever: are we treating depression or inflammation?
Ozçakar L; Onat AM; Kaymak SU; Ureten K; Akinci A
Rheumatol Int; 2005 May; 25(4):319-20. PubMed ID: 15449025
[No Abstract] [Full Text] [Related]
6. Can the Thiol/Disulfide Imbalance Be a Predictor of Colchicine Resistance in Familial Mediterranean Fever?
Omma A; Sandikci SC; Kücüksahin O; Alisik M; Erel O
J Korean Med Sci; 2017 Oct; 32(10):1588-1594. PubMed ID: 28875601
[TBL] [Abstract][Full Text] [Related]
7. Anti-interleukin-1 treatment among patients with familial Mediterranean fever resistant to colchicine treatment. Retrospective analysis.
Sargin G; Kose R; Senturk T
Sao Paulo Med J; 2019 May; 137(1):39-44. PubMed ID: 31116269
[TBL] [Abstract][Full Text] [Related]
8. The Value of Serum Amyloid A Levels in Familial Mediterranean Fever to Identify Occult Inflammation During Asymptomatic Periods.
Çakan M; Karadağ ŞG; Tanatar A; Sönmez HE; Ayaz NA
J Clin Rheumatol; 2021 Jan; 27(1):1-4. PubMed ID: 31524848
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic validity of colchicine in patients with Familial Mediterranean fever.
Ozaltin F; Bilginer Y; Gülhan B; Bajin I; Erdogan O; Hayran M; Yılmaz E; Ozen S
Clin Rheumatol; 2014 Jul; 33(7):969-74. PubMed ID: 24740462
[TBL] [Abstract][Full Text] [Related]
10. Effect of anti-interleukin-1 treatment on quality of life in children with colchicine-resistant familial Mediterranean fever: A single-center experience.
Kurt T; Aydın F; Nilüfer Tekgöz P; Sezer M; Uncu N; Çelikel Acar B
Int J Rheum Dis; 2020 Jul; 23(7):977-981. PubMed ID: 32558310
[TBL] [Abstract][Full Text] [Related]
11. Do all colchicine preparations have the same effectiveness in patients with familial Mediterranean fever?
Baglan E; Ozdel S; Bulbul M
Mod Rheumatol; 2021 Mar; 31(2):481-484. PubMed ID: 32613873
[TBL] [Abstract][Full Text] [Related]
12. Is there a relationship between serum omentin level and acute phase response in patients with familial Mediterranean fever?
Can Sandikci S; Omma A; Yucel C; Omma T
Clin Rheumatol; 2021 Feb; 40(2):669-674. PubMed ID: 32623649
[TBL] [Abstract][Full Text] [Related]
13. The significance of urinary beta-2 microglobulin level for differential diagnosis of familial Mediterranean fever and acute appendicitis.
Ugan Y; Korkmaz H; Dogru A; Koca YS; Balkarlı A; Aylak F; Tunc SE
Clin Rheumatol; 2016 Jul; 35(7):1669-72. PubMed ID: 26873102
[TBL] [Abstract][Full Text] [Related]
14. Possible effect of subclinical inflammation on daily life in familial Mediterranean fever.
Ozçakar ZB; Yalçinkaya F; Yüksel S; Acar B; Gökmen D; Ekim M
Clin Rheumatol; 2006 Mar; 25(2):149-52. PubMed ID: 16172947
[TBL] [Abstract][Full Text] [Related]
15. Effects of anti-tumor necrosis factor agents for familial mediterranean fever patients with chronic arthritis and/or sacroiliitis who were resistant to colchicine treatment.
Bilgen SA; Kilic L; Akdogan A; Kiraz S; Kalyoncu U; Karadag O; Ertenli I; Dogan I; Calguneri M
J Clin Rheumatol; 2011 Oct; 17(7):358-62. PubMed ID: 21946459
[TBL] [Abstract][Full Text] [Related]
16. Which definition should be used to determine colchicine resistance among patients with familial Mediterranean fever?
Erden A; Batu ED; Sarı A; Sönmez HE; Armagan B; Demir S; Fırat E; Bilginer Y; Bilgen SA; Karadağ Ö; Kalyoncu U; Kiraz S; Ertenli I; Özen S; Akdogan A
Clin Exp Rheumatol; 2018; 36(6 Suppl 115):97-102. PubMed ID: 30418112
[TBL] [Abstract][Full Text] [Related]
17. Mean platelet volume in children with familial Mediterranean fever.
Makay B; Türkyilmaz Z; Unsal E
Clin Rheumatol; 2009 Aug; 28(8):975-8. PubMed ID: 19283330
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of long-term treatment with intravenous colchicine for familial Mediterranean fever (FMF) refractory to oral colchicine.
Grossman C; Farberov I; Feld O; Livneh A; Ben-Zvi I
Rheumatol Int; 2019 Mar; 39(3):517-523. PubMed ID: 30604205
[TBL] [Abstract][Full Text] [Related]
19. Acute phase response in familial Mediterranean fever.
Korkmaz C; Ozdogan H; Kasapçopur O; Yazici H
Ann Rheum Dis; 2002 Jan; 61(1):79-81. PubMed ID: 11779767
[TBL] [Abstract][Full Text] [Related]
20. Treatment of colchicine-resistant Familial Mediterranean fever in children and adolescents.
Eroglu FK; Beşbaş N; Topaloglu R; Ozen S
Rheumatol Int; 2015 Oct; 35(10):1733-7. PubMed ID: 26001859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
